RxDoctor Payments DataLook up a doctor →

Erick Cruz, MD

Hematology & Oncology · Mayaguez, PRNPI 1518121821

Payments from drug & device makers

$19,987in general payments, 2019–2025

Across 859 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$3K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • Amgen$1K
  • Genentech USA, Inc.$1K
  • Merck$1K
  • plus $9K from 39 others

What the payments were for

  • Food & beverage$19,50898%
  • Education$4792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,987 in reported general payments places this provider in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$725,705
Medicare patients
25
Services billed
24,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib108$1,101,523
PromactaEltrombopag Olamine82$853,066
FulphilaPegfilgrastim-Jmdb276$582,613
LenvimaLenvatinib Mesylate22$537,858
RevlimidLenalidomide24$447,034
NerlynxNeratinib Maleate17$363,556
TagrissoOsimertinib Mesylate11$181,236
NinlaroIxazomib Citrate13$170,528
RetacritEpoetin Alfa-Epbx68$120,286
NeulastaPegfilgrastim15$95,371
Lupron DepotLeuprolide Acetate40$89,179
Imatinib Mesylate46$31,014
ProliaDenosumab15$26,650
EligardLeuprolide Acetate51$23,797
Abiraterone Acetate41$18,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$104$1,101,523108 claims
NovartisPromacta$514$853,06682 claims
Eisai Inc.Lenvima$645$537,85822 claims
Bristol Myers SquibbRevlimid$125$447,03424 claims
Puma Biotechnology, Inc.Nerlynx$423$363,55617 claims
AstraZenecaTagrisso$2,319$181,23611 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$162$170,52813 claims
PfizerRetacrit, Eliquis$221$128,80081 claims
AmgenNeulasta, Prolia$1,393$122,02130 claims
AbbVieLupron Depot$1,241$89,17940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →